secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bausch Health Companies Inc. (BHC)
CIK:        0000885590
Form:       8-K/A
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001193125-23-276139
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bausch Health's B+L closes $1.75B acquisition of XIIDRA from Novartis; issues $1.9B in debt
--------------------------------------------------------------------------------

- Bausch + Lomb acquired XIIDRA and other ophthalmology assets from Novartis for $1.75B upfront cash plus up to $750M in milestone payments.
- To finance the acquisition, B+L incurred $1.9B debt: $1.4B 8.375% Senior Secured Notes due 2028 and $500M term B loans.
- Pro forma total assets increase to $27.4B; long-term debt rises to $22.0B; equity decreases slightly.
- Acquired assets historical net assets $1.72B; pro forma adjustments include $125M intangibles reduction and $23M goodwill.
- Bridge Facility of $1.75B canceled upon closing; $1.9B debt issuance replaces it.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885590/000119312523276139/0001193125-23-276139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885590/000119312523276139/d295308d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-276139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer